- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06803706
Biomarqueurs microbiens métabolomiques et intestinaux du traitement de l'arrêt du tabac dans la thérapie médicamenteuse à long terme: un essai contrôlé randomisé
Theoretical Framework: Cigarette smoking is the leading preventable cause of death worldwide, with nicotine dependence notably common among individuals with Substance Use Disorders (SUD). Smoking exacerbates both physical and mental health issues, further complicating the treatment of SUD. Current therapeutic approaches for SUD often prove inadequate, indicating a need for new strategies. Recent advancements in metabolomics and gut microbiome research have provided valuable insights into the biological mechanisms underlying addiction.
Objectives: This study aims to investigate the therapeutic potential of smoking cessation for individuals with SUD, using a six-week intervention within a therapeutic community. The research specifically explores the psychobehavioral, metabolic, and gut microbiome domains. It is hypothesized that smoking cessation will improve emotional regulation, self-efficacy, and reduce substance craving, mediated by changes in metabolic and microbiome profiles linked to brain reward systems.
Methods: A randomized controlled trial (N=150) will be conducted, examining outcomes such as clinical relapse rates, microbial and metabolic markers, particularly in choline and folate metabolism. Participants with SUD (n=100) will undergo a six-week smoking cessation intervention, with pre- and post-assessments, compared to a control group receiving treatment as usual. Metabolomic and microbiome analyses will be conducted using blood and stool samples, alongside psychological assessments via questionnaires. Assessments on a behavioural level will take place at a 3-months follow-up.
A cross-sectional, non-interventional healthy control group (n=50) will be examined at a single timepoint with an anologous panel of psychological variables, blood and stool to ascertain differences between smokers with SUD and healthy controls.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Fehring, L'Autriche, 8350
- Grüner Kreis Organization Johnsdorf Facility
-
Graz, L'Autriche, 8036
- Medical University Graz
-
Vienna, L'Autriche, 1020
- Sigmund Freud Private University Vienna
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- diagnosis of a form of substance use disorder (F1x.x) by a licensed psychiatrist according to ICD-10
- minimum age of 18 years
- sufficient knowledge of the German language
- willingness to quit smoking
- willingness and ability to consent
Inclusion criteria for healthy controls :
- minimum age of 18 years
- sufficient knowledge of the German language
- willingness and ability to consent
Exclusion Criteria:
- lack of consent, inability to provide informed consent
- age below 18,
- acute psychotic symptoms or acute suicidal tendencies
- cardiovascular disease
- pregnancy or breastfeeding
- severe mental or organic illnesses (such as epilepsy, brain tumors, recent major surgery), tumor diseases, dementia (Mini Mental Score <20), severe autoimmune diseases or immunosuppression, acute infections, or acute diarrhea, prior gastrointestinal surgery (except appendectomy)
- probiotic intake within the last 6 months,
- ongoing consumtion of dietary supplements, probiotics, antibiotics, or prebiotic supplements during the study
- prior participation in a smoking cessation programme
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Treatment As Usual
Patients in the TAU group receive long-term rehabilitation drug treatment according to the 'community as a treatment'-model |
The standard treatment within the 'Grüner Kreis' therapeutic community - which all participants will receive - consists of group therapy (once a week), individual psychotherapy (once a week), counselling by social workers, psychiatric consultations, as well as sport-, art- and work-therapy. Daily life is organized according to principles of therapeutic community-based addiction treatment. |
|
Expérimental: 6-weeks smoking cessation cognitive-behavioral therapy intervention
The "smoke free in 6 weeks" program is a standardized behavioural therapy intervention that takes place once a week for 1.5 hours over 6 weeks and is provided by the Austrian health insurance provider Österreichische Gesundheitskasse (ÖGK). |
The standard treatment within the 'Grüner Kreis' therapeutic community - which all participants will receive - consists of group therapy (once a week), individual psychotherapy (once a week), counselling by social workers, psychiatric consultations, as well as sport-, art- and work-therapy. Daily life is organized according to principles of therapeutic community-based addiction treatment. Held in the therapeutic community, the intervention will employ principles of cognitive-behavioural therapy (CBT) coupled with personalized recommendations for nicotine replacement. The Austrian Health Insurance standard for therapy will be guiding the program's content, which is tailored for inpatient clients. Specifically, the following interventions based on CBT techniques will be applied in the weekly group sessions consisting of 10 to 15 participants: Psychoeducation including information on tobacco addiction, health risks, advice on relapse prevention and the handling of craving, motivation building, behavioural observation. |
|
Aucune intervention: Healthy controls
Control group with n=50 healthy adult subjects, examined at a single timepoint. No interventions will be administered in this arm. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Self-efficacy
Délai: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period
|
Self-efficacy as a psychological variable and will be assessed by the Self-Efficacy Scale (SWE), a self-report instrument for measuring general optimistic self-confidence. It consists of 10 items and measures optimistic competence expectancy, i.e., confidence in solving difficult situations with one's own abilities. |
From enrollment to follow-up 3 months after the end of the 6-weeks treatment period
|
|
General substance-related craving
Délai: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
|
Substance related craving will be assessed by the MaCS (Mannheim Craving Scale). consists of 12 items and four additional items and is rated on a 5- point Likert scale. |
From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
|
|
Tobacco dependence
Délai: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
|
Tobacco dependence will be assessed by The Fagerström Test for Cigarette Dependence (formerly Fagerström Test for Nicotine Dependence; FTND). It consists of 6 categorically scaled items that assess the number of smoked cigarettes per day (CPD), compulsive use, and dependence intensity. |
From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
|
|
Primary Affects
Délai: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
|
Primary Affects, as proposed by Jaak Panksepp will be assessed by the German Version of the Brief Affective Neuroscience Personality Scales including a LUST Scale (BANPS-GL), a self-report questionnaire. |
From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
|
|
Metabolome
Délai: From enrollment to the end of the 6-weeks treatment period.
|
Metabolome will be ascertained from blood via state-of-the-art NMR (nuclear magnetic resonance). |
From enrollment to the end of the 6-weeks treatment period.
|
|
Gut microbiome
Délai: From enrollment to the end of the 6-weeks treatment period.
|
Gut microbiome will be ascertained via 16s-rRNA sequencing from stool. |
From enrollment to the end of the 6-weeks treatment period.
|
|
Smoking behaviour
Délai: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
|
Participants will be asked regarding their daily smoked cigarettes in the last two weeks (interval scaled). A second single item question will be, if participants have been completely abstinent from tobacco smoking in the last two weeks (dichotome). |
From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Psychiatric Symptoms
Délai: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
|
For the evaluation of psychopathology, the ICD-10 Symptom Rating (ISR) questionnaire will be utilized. In accordance with the ICD-10, this self-assessment questionnaire, comprising 30 items, is designed to comprehensively assess the status and severity of mental disturbances. Symptoms of the six symptomatic patterns - depressive, anxiety, obsessive-compulsive, eating disorders, somatoform syndrome, and post-traumatic stress disorder - are assessed. |
From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Publications et liens utiles
Publications générales
- Fuchshuber J, Schober H, Wohlmuth M, Senra H, Rominger C, Schwerdtfeger A, Unterrainer HF. The effectiveness of a standardized tobacco cessation program on psychophysiological parameters in patients with addiction undergoing long-term rehabilitation: a quasi-experimental pilot study. BMC Med. 2024 May 1;22(1):184. doi: 10.1186/s12916-024-03405-z.
- Peter J, Pritz A, Hiebler M, Mahmoudi M, Fuchshuber J, Morkl S, Holasek S, Humer E, Unterrainer HF. Metabolomic and gut microbial biomarkers of smoking cessation treatment in long-term drug therapy: a study protocol for a randomized controlled trial. Front Psychiatry. 2026 Mar 3;17:1677235. doi: 10.3389/fpsyt.2026.1677235. eCollection 2026.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 1155/2024
- 1155/2024 (Autre identifiant: Ethikkommission der Medizinischen Universität Graz)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .